FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Parsons James T.
 2. Date of Event Requiring Statement (Month/Day/Year)
12/06/2018		 3. Issuer Name and Ticker or Trading Symbol
DiaMedica Therapeutics Inc. [DMAC]
(Last)
(First)
(Middle)
2 CARLSON PARKWAY, SUITE 260		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

MINNEAPOLIS, MN 55447		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Voting Common Shares, no par value per share 3,850 (1)
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   (2) 12/01/2025 Voting Common Shares 12,000 $ 2.26 (3) D  
Stock Option (right to buy)   (4) 11/28/2026 Voting Common Shares 5,000 $ 3.91 (3) D  
Stock Option (right to buy)   (5) 06/19/2027 Voting Common Shares 5,000 $ 4.82 (3) D  
Stock Option (right to buy)   (6) 04/17/2028 Voting Common Shares 3,000 $ 8.43 (3) D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Parsons James T.
2 CARLSON PARKWAY
SUITE 260
MINNEAPOLIS, MN 55447		   X      

Signatures

/s/ Amy Culbert, attorney-in-fact 12/06/2018
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.
(2) This stock option vests in 12 equal quarterly installments over three years starting on March 1, 2016.
(3) Represents the conversion of the exercise price from CAD$ to US$ on November 30, 2018.
(4) This stock option vests in 12 equal quarterly installments over three years starting on February 28, 2017.
(5) This stock option vests in 12 equal quarterly installments over three years starting on September 19, 2017.
(6) This stock option vests in 12 equal quarterly installments over three years starting on July 17, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.